Latest News about AMGN
Recent news which mentions AMGN
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
September 28, 2023
From InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
September 27, 2023
From Benzinga
From MarketWatch
If you think stocks have gotten too expensive, this ETF’s strategy may work for your portfolio
September 26, 2023
From MarketWatch
Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.
September 26, 2023
From MarketWatch
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
From Benzinga
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
From Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
From Benzinga
Why Shares of Neumora Therapeutics Slumped This Week
September 21, 2023
From Motley Fool
2 Dividend Growth Stocks to Buy Right Now
September 21, 2023
From Motley Fool
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
September 13, 2023
Tickers
AMGN
From Benzinga
2 Top Dividend Stocks to Buy in September
September 13, 2023
From Motley Fool
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
September 13, 2023
From Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
September 12, 2023
From InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
From Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
From Benzinga
These four Dow stocks take top prizes for dividend growth
September 06, 2023
From MarketWatch
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
September 05, 2023
From Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
September 05, 2023
From Motley Fool
The 3 Most Promising Dow Stocks to Own Now
September 03, 2023
From InvestorPlace
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
From Motley Fool
As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs
September 01, 2023
From MarketWatch
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
September 01, 2023
From Benzinga
FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
September 01, 2023
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.